POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider…
- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2…
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel…
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed…
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology…
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage…
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in…
Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30…
As the vendor of choice, Progyny’s comprehensive benefit with proven clinical outcomes will be recommended to the more than 220…
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce…